208 related articles for article (PubMed ID: 36472139)
1. Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain.
Vudumula U; Patidar M; Gudala K; Karpf E; Adlard N
J Med Econ; 2023; 26(1):11-18. PubMed ID: 36472139
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
Gärtner J; Hauser SL; Bar-Or A; Montalban X; Cohen JA; Cross AH; Deiva K; Ganjgahi H; Häring DA; Li B; Pingili R; Ramanathan K; Su W; Willi R; Kieseier B; Kappos L
Mult Scler; 2022 Sep; 28(10):1562-1575. PubMed ID: 35266417
[TBL] [Abstract][Full Text] [Related]
3. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
5. To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis.
Montgomery SM; Green L; Karoui H; Nicholas R; Loh J
J Med Econ; 2023; 26(1):139-148. PubMed ID: 36546701
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
Hauser SL; Zielman R; Das Gupta A; Xi J; Stoneman D; Karlsson G; Robertson D; Cohen JA; Kappos L
Mult Scler; 2023 Oct; 29(11-12):1452-1464. PubMed ID: 37691530
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
Soini E; Joutseno J; Sumelahti ML
Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
[TBL] [Abstract][Full Text] [Related]
8. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
[TBL] [Abstract][Full Text] [Related]
9. Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.
Bhan V; Clift F; Baharnoori M; Thomas K; Patel BP; Blanchette F; Adlard N; Vudumula U; Gudala K; Dutta N; Grima D; Mouallif S; Farhane F
J Comp Eff Res; 2023 Sep; 12(9):e220175. PubMed ID: 37606897
[No Abstract] [Full Text] [Related]
10. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.
Ziemssen T; Arnold DL; Alvarez E; Cross AH; Willi R; Li B; Kukkaro P; Kropshofer H; Ramanathan K; Merschhemke M; Kieseier B; Su W; Häring DA; Hauser SL; Kappos L; Kuhle J
Front Immunol; 2022; 13():852563. PubMed ID: 35432382
[TBL] [Abstract][Full Text] [Related]
11. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
12. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L;
N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China.
Xu Y; Mao N; Chirikov V; Du F; Yeh YC; Liu L; Liu R; Gao X
Clin Drug Investig; 2019 Mar; 39(3):331-340. PubMed ID: 30684251
[TBL] [Abstract][Full Text] [Related]
14. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy.
Lazzaro C; Bergamaschi R; Zaffaroni M; Totaro R; Paolicelli D
Neurol Sci; 2022 Aug; 43(8):4933-4944. PubMed ID: 35420360
[TBL] [Abstract][Full Text] [Related]
16. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Hauser SL; Cross AH; Winthrop K; Wiendl H; Nicholas J; Meuth SG; Giacomini PS; Saccà F; Mancione L; Zielman R; Bagger M; Das Gupta A; Häring DA; Jehl V; Kieseier BC; Pingili R; Stoneman D; Su W; Willi R; Kappos L
Mult Scler; 2022 Sep; 28(10):1576-1590. PubMed ID: 35229668
[TBL] [Abstract][Full Text] [Related]
17. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
Zhang Y; Yin H; Zhang D; Xu Y; Peng B; Cui L
J Neurol; 2022 Sep; 269(9):4808-4816. PubMed ID: 35403875
[TBL] [Abstract][Full Text] [Related]
19. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
20. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
